Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes

Tip Ranks
2025.04.03 15:27
portai
I'm PortAI, I can summarize articles.

Virpax Pharmaceuticals (VRPX) has received a delisting notice from the Nasdaq due to non-compliance with stockholders’ equity requirements, with trading suspension set for April 4, 2025. The delisting will be finalized after the appeal period. Concurrently, several board members and the CFO resigned without citing disagreements. The company has seen a year-to-date price performance decline of 87.16% and currently has a market cap of $1.59M.

Virpax Pharmaceuticals ( (VRPX) ) has provided an update.

On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.

More about Virpax Pharmaceuticals

YTD Price Performance: -87.16%

Average Trading Volume: 364,334

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.59M

Learn more about VRPX stock on TipRanks’ Stock Analysis page.

Trending Articles:

  • WBA Lawsuit Alert! Class Action Lawsuit Against Walgreens Boots Alliance
  • 3 Penny Stocks to Watch Now, 4/3/25
  • ‘Get Your Popcorn Ready,’ Says Investor About CoreWeave Stock

Disclaimer & DisclosureReport an Issue

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.